AbstractPurpose: Baseline neutrophil count may predict overall survival (OS) in patients with locally advanced...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Int J Radiat Oncol Biol Phys
AbstractAflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the...
Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Int J Oncol .
ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...
Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes
AbstractObjective: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic...
Posté par : Mme. Julie HENRIQUES, Pr. Franck BONNETAIN
Nom de la revue : BJU Int
AbstractThe objective of this study was to assess the psychometric properties of the French version of the Supportive...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Journal of Cancer Care
AbstractPurpose The inclusion of patient-reported outcome (PRO) questionnaires in prognostic factor analyses in...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Quality of Life Research
ABSTRACTIntroduction While there is mounting evidence of the independent prognostic value of patient-reported outcomes...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : BMJ Open
AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....
Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol
Letter to editor.LINK
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : European Journal of Cancer
ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...
Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology
BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol
ABSTRACTBackground and objective: Health-related quality of life (HRQoL) has become one relevant and...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Computer Methods and Programs in Biomedicine
With advances in breast cancer (BC) gene panel testing, risk counseling has become increasingly complex, potentially...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : International Journal of Environmental Research and Public Health
AbstractBACKGROUND:Current prognostic systems for myelodysplastic syndromes (MDS) are based on clinical, pathologic, and...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Cancer
AbstractBackgroundWe studied the relationship between intermediate criteria and overall survival (OS) in metastatic...
Posté par : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Clinical Colorectal Cancer
Advances in cancer care delivery require revision and further development of questionnaires assessing patients’...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Journal of Cancer Care
AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer
Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...
Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst
Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology
AbstractTraditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology